Overview

Helios Bioelectronics Inc. Company IntroductionFounded in 2016, Helios Bioelectronics Inc. is an innovative biotechnology company dedicated to integrating semiconductor technology with biomarker detection. 

The company’s initial goal was to combine advanced semiconductor technology with biological diagnostics to develop efficient and precise diagnostic tools, advancing healthcare and drug development. Through collaborations with Taiwan Semiconductor Manufacturing Company (TSMC) and Episil Technologies, Helios has successfully developed two cutting-edge biochip systems, demonstrating its exceptional capability in merging biotechnology with semiconductor technology.

Core Technologies and Products

1. CMOS-Based Biochip System

Developed in collaboration with TSMC, the CMOS (Complementary Metal-Oxide-Semiconductor) biochip system is designed for multiplexing, enabling simultaneous detection of multiple biomarkers and rapid collection of extensive biological data. With high-throughput capabilities, this system is ideal for artificial intelligence (AI) analysis and applications in disease diagnosis and drug development. Its high integration and flexibility make it highly promising for precision medicine.

2. Nanowire Field Effect Transistor (FET) System

In partnership with Episil Technologies, Helios developed a nanowire FET system with ultra-high sensitivity for detecting trace biomarkers. This system is particularly suited for high-precision biological detection scenarios, such as early disease diagnosis or tracking specific biomarkers. Its exceptional sensitivity provides a unique advantage in trace analysis.

New Application: Trace Metal Ion Detection

In recent years, Helios has validated the application of both systems in trace metal ion detection, successfully addressing the limitations of traditional inductively coupled plasma mass spectrometry (ICP-MS) in sensitivity and portability. This breakthrough expands the potential of its technology in environmental monitoring, food safety, and other industrial applications. Especially well-suited for monitoring the quality of various solutions used in advanced semiconductor manufacturing processes.

Technical Advantages: Miniaturization and Point-of-Care Testing (POCT)

Both of Helios’ systems feature miniaturization, making them suitable for point-of-care testing (POCT). This enables their products to be easily applied in hospitals, clinics, or even home settings, delivering fast and convenient testing to meet the modern healthcare demands for immediacy and accessibility.

Future Outlook

Helios Bioelectronics is actively seeking partnerships with major corporations to accelerate product development, mass production, and market expansion. Through strategic alliances with industry leaders, the company aims to bring its cutting-edge technology to the global market, with applications in medical diagnostics, drug development, environmental monitoring, and more, injecting new momentum into precision medicine and smart healthcare.With its unique strengths in integrating biochips with semiconductor technology and a keen understanding of market needs, Helios Bioelectronics is steadily emerging as a leader in the biotechnology sector, with a highly promising future. 
Leveraging its unique strengths in integrating biochip and semiconductor technologies, along with its keen understanding of market needs, Helios Bioelectronics is steadily emerging as a leading enterprise in the biotechnology sector, with promising prospects for future development.